Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,407 | -5,264 | -6,472 | -34,197 |
| Stock-based compensation | 1,497 | 3,316 | 2,984 | 3,610 |
| Accretion of debt discount | NaN | 0 | NaN | NaN |
| Gain on settlement of accounts payable | -91 | -1,252 | 626 | NaN |
| Depreciation expense | 52 | 56 | 28 | NaN |
| Deferred liabilities | NaN | 0 | -511 | -6 |
| Impairment of acquired in-process research and development intangible assets | NaN | 0 | 0 | 16,514 |
| Research and development tax credit receivable | -3,805 | 2,580 | 99 | 424 |
| Other tax receivable | 34 | -503 | 210 | 322 |
| Accretion of debt discount | NaN | NaN | NaN | 0 |
| Prepaid expenses | 99 | 123 | -33 | 174 |
| Prepaid expenses related party | NaN | 0 | NaN | 0 |
| Accounts payable and accrued liabilities related parties | NaN | NaN | NaN | 159 |
| Other assets | 88 | -151 | 176 | 491 |
| Accounts payable and accrued liabilities | -3,018 | 893 | -170 | 1,132 |
| Operating lease liabilities | -20 | 104 | -61 | NaN |
| Net cash used in operating activities | -3,403 | -2,944 | -5,439 | -14,199 |
| Purchase of fixed assets | NaN | 143 | 193 | 706 |
| Net cash used in investing activities | NaN | -143 | -193 | -706 |
| Net proceeds from sale of common stock and warrants | NaN | 0 | 0 | 27,544 |
| Repayments of debt | NaN | NaN | NaN | 0 |
| Cash proceeds for amendment of warrants | NaN | 67 | NaN | NaN |
| Exercise of warrants for cash | NaN | 0 | 0 | 1 |
| Net cash provided by financing activities | NaN | 67 | 0 | 27,545 |
| Impact on cash from foreign currency translation | 10 | 37 | -8 | -188 |
| Net decrease in cash and cash equivalents | -3,393 | -2,983 | -5,640 | 12,452 |
| Cash and cash equivalents at beginning of period | 24,751 | 27,734 | 20,922 | NaN |
| Cash and cash equivalents at end of period | 21,358 | 24,751 | 27,734 | NaN |